FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to a method of treating multiple myeloma, involving administering elranatamab to an individual in an introduction schedule with different doses and frequency of administration depending on the number of weeks.
EFFECT: clinical effectiveness in multiple myeloma.
18 cl, 8 dwg, 19 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF MONOCLONAL ANTIBODIES OF OX40 AGONIST AND 4-1BB AGONIST FOR CANCER TREATMENT | 2017 |
|
RU2748949C2 |
| METHOD OF TREATMENT OF ATOPIC DERMATITIS THROUGH INTRODUCTION OF IL-4R INHIBITOR | 2019 |
|
RU2801204C2 |
| ANTIBODIES TO CD40 FOR USE IN THE TREATMENT OF SJOGREN'S SYNDROME | 2018 |
|
RU2790558C2 |
| METHODS OF TREATING ATOPIC DERMATITIS BY ADMINISTERING IL-4R ANTAGONIST | 2020 |
|
RU2828020C2 |
| ANTIBODIES TO B7-H1 AND CTLA-4 FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER | 2015 |
|
RU2806210C2 |
| PHARMACEUTICAL COMPOSITION INTENDED FOR USE FOR TREATMENT OR PREVENTION OF C5-RELATED DISEASE AND METHOD FOR TREATMENT OR PREVENTION OF C5-RELATED DISEASE | 2019 |
|
RU2789389C2 |
| METHODS FOR PREVENTING OR TREATING ALLERGIES BY INTRODUCING AN IL-4R ANTAGONIST | 2017 |
|
RU2777328C2 |
| METHODS FOR USING CD32B x CD79B-BINDING MOLECULES IN TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | 2017 |
|
RU2772434C2 |
| MOLECULES OF ANTIBODIES TO CD73 AND THEIR APPLICATION WAYS | 2018 |
|
RU2791192C2 |
| TREATING CANCER WITH COMBINATION OF PD-1 ANTAGONIST AND DINACICLIB | 2014 |
|
RU2705795C2 |
